Developer docs
API playgroundTry for free, no card

Search company profiles

DoMore Diagnostics

Full company profile

uuid00085vl

Namestring
DoMore Diagnostics
Legal namestring
DoMore Diagnostics AS
Company typeenum
Private
Founded yearint
2021
Descriptiontext

DoMore Diagnostics is a Norwegian AI-powered digital pathology company that has developed Histotype Px® Colorectal, a CE-IVDD marked deep learning biomarker that analyzes standard H&E-stained whole-slide images to predict outcomes and adjuvant chemotherapy (ACT) benefit for stage II and III colorectal cancer patients. The algorithm stratifies patients into Low, Intermediate, and High-risk groups, and was originally published in The Lancet (2020) with extended results in The Lancet Oncology (2022); the underlying intellectual property is held under a global exclusive license from Oslo University Hospital's Institute for Cancer Genetics and Informatics (ICGI), where the CTO and the late Prof. Håvard Danielsen co-developed the method. The company is built on research from Oslo University Hospital, Oxford University, and University College London, and was selected as a Lighthouse project by the Norwegian Research Council.

The product analyzes routine histology slides with no additional tissue or wet-lab work required, and can be combined with circulating tumor DNA (ctDNA) minimal residual disease testing — a combination validated in the CIRCULATE-Japan GALAXY trial (n=1,082) and forthcoming CIRCULATE-FRANCE PRODIGE 70 study (n=500). Histotype Px® is offered as a CE-IVDD clinical product in the EU and as Research Use Only elsewhere, with three granted US patents and first patents in Japan and Korea protecting the method across major oncology markets. Internally, the company has AI Engineers, a Senior Software Developer, a Product Manager, a Head of Quality and Regulatory, and a Medical Director, and a Scientific Advisory Board that includes international KOLs from UMC Utrecht, Mayo Clinic, and the NCC Japan.

Commercially, DoMore Diagnostics operates a hybrid go-to-market: a direct quote-based test-ordering channel via its website and distribution through four major digital pathology platforms — Paige's AppLab™ Marketplace, PathAI's AISight™ Image Management System, Sectra's Amplifier Marketplace, and Proscia's Concentriq® Dx — giving the small team access to the largest installed bases of digital pathology customers globally. Revenue is generated from per-test fees and platform licensing economics, with the largest single capital event being up to €10 million in EIC Accelerator financing (€2.5M grant + up to €7.5M equity) awarded in February 2024 alongside a NOK 16M Research Council of Norway grant. The current commercial footprint is EU-focused under CE-IVDD, with research collaborations and validation work extending into the US, the Netherlands, Denmark, France, and Japan ahead of broader regulatory clearance.

Short descriptiontext

DoMore Diagnostics develops Histotype Px® Colorectal, a CE-IVDD deep-learning biomarker that analyzes H&E histology slides to predict outcomes and guide adjuvant chemotherapy decisions for stage II/III colorectal cancer patients, distributed through Paige, PathAI, Sectra, and Proscia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersOslo, Norway
HQ citystring
Oslo
HQ countrystring
Norway
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital pathology biomarkers, AI cancer diagnostics, colorectal cancer biomarkers, histology image analysis, deep learning pathology
Industry3 codes
PRIMARYHLAAAMAI
Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAMAF
Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code2 codes
  • Medical and Diagnostic Laboratories62151
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Digital Pathology Diagnostics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Histotype Px® Colorectal Test Sales
TypeSubscription Recurring
Description

Revenue generated from laboratory test orders for Histotype Px® Colorectal digital biomarker analysis. Healthcare providers submit tumor tissue samples for AI-powered analysis that predicts patient outcomes and guides adjuvant chemotherapy decisions. The test is available through direct ordering on the company website and through integrated pathology platforms.

domorediagnostics.com
2Platform Licensing
TypeLicensing Royalties
Description

Technology licensing arrangements with digital pathology platform providers (Paige, PathAI, Sectra, Proscia) enabling integration of Histotype Px® into their enterprise pathology platforms, potentially generating licensing fees or revenue sharing.

domorediagnostics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

DoMore Diagnostics develops and sells Histotype Px Colorectal, a CE-IVDD marked deep learning digital biomarker that analyzes routine H&E-stained whole-slide histology images to predict patient outcomes and guide adjuvant chemotherapy treatment decisions for stage II and III colorectal cancer patients. The product classifies patients into Low, Intermediate, and High-risk groups and is delivered either as a cloud-based analysis service or through integration with major enterprise digital pathology platforms (Paige, PathAI, Sectra, Proscia) for use by hospital pathology laboratories.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Stage II/III colorectal cancer patients risk-stratified into Low, Intermediate, and High-risk groups for adjuvant chemotherapy decisions
+4 more records
Product overview1 text field

DoMore Diagnostics offers a single unified product: the Histotype Px Colorectal digital biomarker. This AI-powered tool analyzes routine hematoxylin and eosin (H&E) stained histology slides to predict patient outcomes and guide personalized adjuvant chemotherapy decisions for colorectal cancer patients. The product is delivered as a cloud-based or platform-integrated clinical decision support tool that can be accessed through commercial partnerships with digital pathology platform providers including Proscia (Concentriq Dx), Sectra, PathAI (AISight), and Paige (AppLab Marketplace).

Product and service1 record
1Histotype Px Colorectal
CategoryDigital Pathology / AI Biomarker
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-12-12
Description

Collaboration with French-speaking Federation of Digestive Cancer (FFCD) and CHU Dijon to clinically validate Histotype Px® Colorectal using samples from the CIRCULATE-FRANCE PRODIGE 70 clinical trial in 500 colorectal cancer patients. Aims to evaluate prognostic performance alone and in combination with ctDNA.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-01-16
Description

Clinical research collaboration to assess prognostic and predictive value of Histotype Px® Colorectal alone and in combination with circulating tumor DNA in Danish stage II and III colorectal cancer patients with comprehensive ctDNA monitoring.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-11-19
Description

Commercial partnership making Histotype Px® Colorectal available on AISight™, PathAI's Image Management System for Digital Pathology. AISight is a cloud-native intelligent enterprise workflow solution used by leading laboratories worldwide for digital pathology workflows and AI applications.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2024-11-11
Description

Research collaboration to clinically validate Histotype Px® Colorectal in up to 2200 stage II and III rectal cancer patients from Snapshot rectum 2011 and 2016 cohorts who have not received adjuvant chemotherapy. Supported by Innovation Project grant from Research Council of Norway.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2024-10-08
Description

Clinical research collaboration with Europe's #1 and world's #4 ranked cancer hospital to clinically validate Histotype Px® Colorectal in French stage II and III colorectal cancer patients using H&E slides and matching biopsies with clinical outcome data.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2024-06-06
Description

Research collaboration to clinically validate Histotype Px® Colorectal in up to 2500 stage II and III colon cancer patients from the PLCRC cohort. Study aims to generate data supporting clinical guideline inclusion and adoption as a digital biomarker to guide ACT treatment decisions.

7Paige
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-02-08
Description

Histotype Px® Colorectal added to Paige's AppLab™ Marketplace, ensuring seamless and easy integration of AI solutions for end users. Paige is a key partner as DoMore continues mission to personalize cancer treatment for patients worldwide.

domorediagnostics.com
8Stavanger University Hospital
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2023-10-19
Description

Collaboration to validate Histotype Px® Colorectal in patients from the ACROBATICC study and test clinical utility of the digital biomarker in Norwegian colorectal cancer patients.

domorediagnostics.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-08-30
Description

Partnership to integrate DoMore Diagnostics' CE-IVDD marked Histotype Px® Colorectal digital biomarker with Proscia's CE-IVDR marked Concentriq® Dx enterprise pathology platform. Collaboration enables AI-powered clinical decision support into routine pathology workflows for colorectal cancer patients.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2023-08-09
Description

Retrospective testing agreement to implement and validate Histotype Px® Colorectal in U.S. patients to determine whether the test can help guide real-life decisions for patients with stage II and III colorectal cancer.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-12-07
Description

Integration of Histotype Px® Colorectal with Sectra's pathology imaging platform via Sectra Amplifier Marketplace, giving Sectra users access to Histotype Px within their existing digital pathology workflow.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

DoMore Diagnostics is based on research from the Institute for Cancer Genetics and Informatics (ICGI) at Oslo University Hospital. The company holds global exclusive license to the patent portfolio underpinning Histotype Px. Ongoing collaboration aims to develop new and better digital biomarkers that are robust for lab and scanner variations.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DoMore Diagnostics

Digital Pathology Diagnosticsdomorediagnostics.com

DoMore Diagnostics develops Histotype Px® Colorectal, a CE-IVDD deep-learning biomarker that analyzes H&E histology slides to predict outcomes and guide adjuvant chemotherapy decisions for stage II/III colorectal cancer patients, distributed through Paige, PathAI, Sectra, and Proscia.

What DoMore Diagnostics does

DoMore Diagnostics is a Norwegian AI-powered digital pathology company that has developed Histotype Px® Colorectal, a CE-IVDD marked deep learning biomarker that analyzes standard H&E-stained whole-slide images to predict outcomes and adjuvant chemotherapy (ACT) benefit for stage II and III colorectal cancer patients. The algorithm stratifies patients into Low, Intermediate, and High-risk groups, and was originally published in The Lancet (2020) with extended results in The Lancet Oncology (2022); the underlying intellectual property is held under a global exclusive license from Oslo University Hospital's Institute for Cancer Genetics and Informatics (ICGI), where the CTO and the late Prof. Håvard Danielsen co-developed the method. The company is built on research from Oslo University Hospital, Oxford University, and University College London, and was selected as a Lighthouse project by the Norwegian Research Council.

The product analyzes routine histology slides with no additional tissue or wet-lab work required, and can be combined with circulating tumor DNA (ctDNA) minimal residual disease testing — a combination validated in the CIRCULATE-Japan GALAXY trial (n=1,082) and forthcoming CIRCULATE-FRANCE PRODIGE 70 study (n=500). Histotype Px® is offered as a CE-IVDD clinical product in the EU and as Research Use Only elsewhere, with three granted US patents and first patents in Japan and Korea protecting the method across major oncology markets. Internally, the company has AI Engineers, a Senior Software Developer, a Product Manager, a Head of Quality and Regulatory, and a Medical Director, and a Scientific Advisory Board that includes international KOLs from UMC Utrecht, Mayo Clinic, and the NCC Japan.

Commercially, DoMore Diagnostics operates a hybrid go-to-market: a direct quote-based test-ordering channel via its website and distribution through four major digital pathology platforms — Paige's AppLab™ Marketplace, PathAI's AISight™ Image Management System, Sectra's Amplifier Marketplace, and Proscia's Concentriq® Dx — giving the small team access to the largest installed bases of digital pathology customers globally. Revenue is generated from per-test fees and platform licensing economics, with the largest single capital event being up to €10 million in EIC Accelerator financing (€2.5M grant + up to €7.5M equity) awarded in February 2024 alongside a NOK 16M Research Council of Norway grant. The current commercial footprint is EU-focused under CE-IVDD, with research collaborations and validation work extending into the US, the Netherlands, Denmark, France, and Japan ahead of broader regulatory clearance.

DoMore Diagnostics firmographics

Firmographics
Name
DoMore Diagnostics
Legal name
DoMore Diagnostics AS
Website
https://domorediagnostics.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
DoMore Diagnostics develops Histotype Px® Colorectal, a CE-IVDD deep-learning biomarker that analyzes H&E histology slides to predict outcomes and guide adjuvant chemotherapy decisions for stage II/III colorectal cancer patients, distributed through Paige, PathAI, Sectra, and Proscia.
Ownership category
akta.pro rank

DoMore Diagnostics industry classification

Industry
Product category
Digital Pathology Diagnostics
NAICS
Medical and Diagnostic Laboratories (62151), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAMAI
Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAMAF
Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Digital pathology biomarkers
  • AI cancer diagnostics
  • Colorectal cancer biomarkers
  • Histology image analysis
  • Deep learning pathology

Where DoMore Diagnostics is headquartered

Location

Headquarters

HQ city
Oslo
HQ country
Norway
HQ region
Europe

Offices1 record

Markets served

DoMore Diagnostics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Histotype Px® Colorectal Test Sales: Revenue generated from laboratory test orders for Histotype Px® Colorectal digital biomarker analysis. Healthcare providers submit tumor tissue samples for AI-powered analysis that predicts patient outcomes and guides adjuvant chemotherapy decisions. The test is available through direct ordering on the company website and through integrated pathology platforms.
  2. Platform Licensing: Technology licensing arrangements with digital pathology platform providers (Paige, PathAI, Sectra, Proscia) enabling integration of Histotype Px® into their enterprise pathology platforms, potentially generating licensing fees or revenue sharing.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

DoMore Diagnostics product offering

Product offering

Core offering

DoMore Diagnostics develops and sells Histotype Px Colorectal, a CE-IVDD marked deep learning digital biomarker that analyzes routine H&E-stained whole-slide histology images to predict patient outcomes and guide adjuvant chemotherapy treatment decisions for stage II and III colorectal cancer patients. The product classifies patients into Low, Intermediate, and High-risk groups and is delivered either as a cloud-based analysis service or through integration with major enterprise digital pathology platforms (Paige, PathAI, Sectra, Proscia) for use by hospital pathology laboratories.

Product overview

DoMore Diagnostics offers a single unified product: the Histotype Px Colorectal digital biomarker. This AI-powered tool analyzes routine hematoxylin and eosin (H&E) stained histology slides to predict patient outcomes and guide personalized adjuvant chemotherapy decisions for colorectal cancer patients. The product is delivered as a cloud-based or platform-integrated clinical decision support tool that can be accessed through commercial partnerships with digital pathology platform providers including Proscia (Concentriq Dx), Sectra, PathAI (AISight), and Paige (AppLab Marketplace).

Differentiator

Problem solved

Functional benefit

Products and services

  • Histotype Px Colorectal

Quantifiable outcome

  • Stage II/III colorectal cancer patients risk-stratified into Low, Intermediate, and High-risk groups for adjuvant chemotherapy decisions
  • +4 more outcomes

Companies that use DoMore Diagnostics

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles2 records

DoMore Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability3 records

Feature3 records

DoMore Diagnostics partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered strategic, core and supporting.

  • FFCD and CHU DijonstrategicStrategic or Co-development Partner · 12 December 2025Collaboration with French-speaking Federation of Digestive Cancer (FFCD) and CHU Dijon to clinically validate Histotype Px® Colorectal using samples from the CIRCULATE-FRANCE PRODIGE 70 clinical trial in 500 colorectal cancer patients. Aims to evaluate prognostic performance alone and in combination with ctDNA.
  • Aarhus University HospitalstrategicStrategic or Co-development Partner · 16 January 2025Clinical research collaboration to assess prognostic and predictive value of Histotype Px® Colorectal alone and in combination with circulating tumor DNA in Danish stage II and III colorectal cancer patients with comprehensive ctDNA monitoring.
  • PathAIcoreTechnology or Integration · 19 November 2024Commercial partnership making Histotype Px® Colorectal available on AISight™, PathAI's Image Management System for Digital Pathology. AISight is a cloud-native intelligent enterprise workflow solution used by leading laboratories worldwide for digital pathology workflows and AI applications.
  • Erasmus MC Cancer InstitutestrategicStrategic or Co-development Partner · 11 November 2024Research collaboration to clinically validate Histotype Px® Colorectal in up to 2200 stage II and III rectal cancer patients from Snapshot rectum 2011 and 2016 cohorts who have not received adjuvant chemotherapy. Supported by Innovation Project grant from Research Council of Norway.
  • Gustave RoussystrategicStrategic or Co-development Partner · 8 October 2024Clinical research collaboration with Europe's #1 and world's #4 ranked cancer hospital to clinically validate Histotype Px® Colorectal in French stage II and III colorectal cancer patients using H&E slides and matching biopsies with clinical outcome data.
  • University Medical Centre Utrecht (UMC Utrecht)strategicStrategic or Co-development Partner · 6 June 2024Research collaboration to clinically validate Histotype Px® Colorectal in up to 2500 stage II and III colon cancer patients from the PLCRC cohort. Study aims to generate data supporting clinical guideline inclusion and adoption as a digital biomarker to guide ACT treatment decisions.
  • PaigecoreTechnology or Integration · 8 February 2024Histotype Px® Colorectal added to Paige's AppLab™ Marketplace, ensuring seamless and easy integration of AI solutions for end users. Paige is a key partner as DoMore continues mission to personalize cancer treatment for patients worldwide.
  • Stavanger University HospitalsupportingStrategic or Co-development Partner · 19 October 2023Collaboration to validate Histotype Px® Colorectal in patients from the ACROBATICC study and test clinical utility of the digital biomarker in Norwegian colorectal cancer patients.
  • ProsciacoreTechnology or Integration · 30 August 2023Partnership to integrate DoMore Diagnostics' CE-IVDD marked Histotype Px® Colorectal digital biomarker with Proscia's CE-IVDR marked Concentriq® Dx enterprise pathology platform. Collaboration enables AI-powered clinical decision support into routine pathology workflows for colorectal cancer patients.
  • The Ohio State University Wexner Medical CenterstrategicStrategic or Co-development Partner · 9 August 2023Retrospective testing agreement to implement and validate Histotype Px® Colorectal in U.S. patients to determine whether the test can help guide real-life decisions for patients with stage II and III colorectal cancer.
  • SectracoreTechnology or Integration · 7 December 2022Integration of Histotype Px® Colorectal with Sectra's pathology imaging platform via Sectra Amplifier Marketplace, giving Sectra users access to Histotype Px within their existing digital pathology workflow.
  • Oslo University Hospital / ICGIcoreStrategic or Co-development PartnerDoMore Diagnostics is based on research from the Institute for Cancer Genetics and Informatics (ICGI) at Oslo University Hospital. The company holds global exclusive license to the patent portfolio underpinning Histotype Px. Ongoing collaboration aims to develop new and better digital biomarkers that are robust for lab and scanner variations.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

DoMore Diagnostics competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key highlights7 records

Customer concentration

DoMore Diagnostics social profiles

Digital presence

DoMore Diagnostics compliance and trust

Trust signal

Compliance2 records

DoMore Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DoMore Diagnostics leadership team

Management profile

Number of profiles

Profiles15 records

DoMore Diagnostics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DoMore Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DoMore Diagnostics

What does DoMore Diagnostics do?

DoMore Diagnostics develops and sells Histotype Px Colorectal, a CE-IVDD marked deep learning digital biomarker that analyzes routine H&E-stained whole-slide histology images to predict patient outcomes and guide adjuvant chemotherapy treatment decisions for stage II and III colorectal cancer patients. The product classifies patients into Low, Intermediate, and High-risk groups and is delivered either as a cloud-based analysis service or through integration with major enterprise digital pathology platforms (Paige, PathAI, Sectra, Proscia) for use by hospital pathology laboratories.

Is DoMore Diagnostics a public or private company?

DoMore Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.

When was DoMore Diagnostics founded?

DoMore Diagnostics was founded in 2021. It employs 11 to 50 people.

Where is DoMore Diagnostics based?

DoMore Diagnostics is headquartered in Oslo, Norway, in the Europe region.

How does DoMore Diagnostics make money?

Two revenue lines are on record. Histotype Px® Colorectal Test Sales are the primary driver. The others are platform Licensing.

Does DoMore Diagnostics have an API?

No public API is recorded for DoMore Diagnostics.

What industry is DoMore Diagnostics in?

DoMore Diagnostics's product category is Digital Pathology Diagnostics. Its primary akta.pro industry code is HLAAAMAI, Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers), with a secondary code of HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy). Its NAICS code is 62151 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PaigePathAI Announces Integrations with Leading AI-pathology companies Deep Bio, DoMore Diagnostics, Paige, and Visiopharm, through its AISight Image Management System — Paige.aiPathAI announced the integration of several AI products from digital pathology companies Deep Bio, DoMore Diagnostics, Paige, and Visiopharm into its AISight Image Management System in Boston, MA on November 19, 2024. These collaborations aim to enhance diagnostics and improve patient care by providing access to advanced algorithms and streamlining pathology workflows. The integrations signal PathAI's commitment to interoperability and advancing digital pathology solutions.YahooPathAI Announces Integrations with Leading AI-pathology Companies Deep Bio, DoMore Diagnostics, Paige, and Visiopharm, through its AISight Image Management SystemPathAI announced integrations of AI products from Deep Bio, DoMore Diagnostics, Paige, and Visiopharm into its AISight Image Management System. The collaborations bring algorithms from these companies directly into the platform, aiming to enhance interoperability and workflow efficiency for pathologists.PathaiPathAI Announces Integrations with Leading AI-pathology companies Deep Bio, DoMore Diagnostics, Paige, and Visiopharm, through its AISight Image Management SystemPathAI announced the integration of AI pathology algorithms from Deep Bio, DoMore Diagnostics, Paige, and Visiopharm into its AISight Image Management System. This collaboration allows partner laboratories to access a diverse portfolio of digital pathology solutions directly within the PathAI platform, aiming to streamline workflows and improve diagnostic accuracy. The move reinforces PathAI's commitment to building a robust ecosystem of interoperable AI tools for the digital pathology market.Domorediagnosticsawarded up to €10 million financing — DoMore DiagnosticsDoMore Diagnostics has been awarded up to €10 million in grant and equity financing by the European Innovation Council (EIC) Accelerator program to support the commercial launch of its digital biomarker, Histotype Px® Colorectal. The funding package includes a €2.5 million non-dilutive grant and up to €7.5 million in equity matching from the EIC Fund.